Reader response: Evidence in focus: Nusinersen use in spinal muscular atrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Nusinersen is effective for patients with spinal muscular atrophy (SMA) and has been approved in the United States, Europe, and Japan.1 No life-threatening adverse events have been reported in clinical trials; however, 5 patients with communicating hydrocephalus were shown without detailed information.2 We, herein, report a patient with SMA type 1 showing communicating hydrocephalus related to nusinersen treatment.

Source link

Related posts

Sphenopalatine Ganglion Blockade Improves Connectivity in Medication Overuse Headache


12 Ways to Avoid Depression This Holiday Season


Spotlight on the March 26 issue


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy